15 results about "Bacterial lysate" patented technology

The invention discloses bifidobacterium breve CCFM1505 capable of regulating skin ceramide de novo synthesis and improving skin health and a metagen thereof, and belongs to the technical field of microorganisms and medicines. The bifidobacterium breve CCFM1505 obtained through screening shows the effect of remarkably promoting skin ceramide synthesis in the aspects of external use and oral administration. The viable bacteria of the bifidobacterium breve CCFM1505 and the metabiotics thereof, especially the thallus lysate of the bifidobacterium breve, are orally taken, so that the content of ceramide in the skin tissue is remarkably increased, and meanwhile, the effects of increasing of transpedermis water loss, reducing of the water content of cuticle and inflammatory response caused by skin injury and reducing of the ceramide content can be effectively regulated and controlled, and the skin healing effect is improved. Therefore, the skin health is improved. Therefore, the bifidobacterium breve has a huge application prospect in preparation of external or oral medicines for promoting synthesis of skin ceramide and improving skin health, as well as in preparation of foods, health-care products or cosmetics.

This invention relates to the field of microbial pharmaceutical technology, specifically disclosing the application of *Blautia Obeum* in the preparation of drugs for the prevention and treatment of depression, representing a novel use of probiotics for antidepressant purposes. This invention is the first to apply *Blautia Obeum* to the prevention and treatment of depression. This strain can be prepared in various forms, including live bacterial preparations, inactivated bacterial cells, bacterial lysates, metabolites, or bacterial extracts, combined with pharmaceutically acceptable excipients to formulate various oral microecological preparations, including conventional dosage forms such as tablets, capsules, enteric-coated preparations, and oral liquids. The drugs can effectively improve core clinical symptoms of depression, such as low mood, loss of interest, sleep disorders, anxiety, and irritability, by regulating intestinal flora homeostasis, repairing intestinal barrier function, and modulating the brain-gut axis signaling pathway. It is suitable for the prevention and treatment of various types of depression, including major depressive disorder, postpartum depression, geriatric depression, and chronic stress-induced depression. The strain used in this invention is safe and highly compatible, and the preparation is convenient to administer, providing a novel microecological intervention scheme for the clinical prevention and treatment of depression, overcoming some limitations of existing antidepressant methods, and possessing good prospects for pharmaceutical development.

TITLE: MIXTURE OF BACTERIA, LYSATE, AND ISOLATED METABOLITES FROM BUHTAN'S CURCUMA LONGA TO INCREASE YIELD AND ANTI-INFLAMMATORY PROPERTIES IN AGRICULTURAL PRODUCTION. The present invention relates to a plant treatment composition characterized in that it contains a mixture of live bacteria, bacterial lysate, and metabolites from the rhizomes of Curcuma longa. Spraying or applying said composition to plants increases plant fertility and enhances the anti-inflammatory properties of cereals, fruits, and vegetables.

The present invention relates to orally administered postbiotic compositions, and discloses orally administered postbiotic compositions used for the treatment of solid tumors in patients, particularly colon cancer and / or lung cancer. The compositions comprise lysates of probiotic microorganisms belonging to the genera Bacillus, Bifidobacterium, Lactobacillus, Saccharomyces, and Streptococcus.

The application belongs to the technical field of inorganic materials and analysis, and particularly relates to a kind of nucleic acid aptamer modified polydopamine coated magnetic composite material MagG@PDA@Au@Aptamer and its preparation and application in selectively separating recombinant histidine tag protein.The material of the application is synthesized by solvothermal method one-step magnetic graphene oxide composite material MagG, then coated with polydopamine to obtain MagG@PDA, then Au is bonded to the surface of MagG@PDA material, and then 5 end modified thiol nucleic acid aptamer is connected to the surface of the material to synthesize nucleic acid aptamer modified polydopamine coated magnetic graphene oxide composite material MagG@PDA@Au@Aptamer.The preparation method of the material of the application is simple, the nucleic acid aptamer solid loading is high, and the recombinant histidine tag protein in bacterial lysate can be separated and enriched efficiently and selectively.

The invention relates to the technical field of biology, in particular to a bacterial nucleic acid extraction kit and application thereof.The bacterial nucleic acid extraction kit comprises a bacterial lysis solution, cellulose microspheres, eluent and a matched nucleic acid extraction device and can efficiently lyse cell walls of gram-negative bacteria and gram-positive bacteria and rapidly purify nucleic acid; the time consumed by the whole nucleic acid extraction link does not exceed 10 minutes, the downstream PCR detection sensitivity can reach 10 <-9 > ng / mu L, and the timeliness and reliability of nucleic acid extraction are remarkably improved.

The invention discloses a lactobacillus acidophilus CCFM1460 capable of generating various bioactive substances to promote skin barrier repair and a metagen thereof, and belongs to the technical field of microorganisms and medicines. The lactobacillus acidophilus CCFM1460 provided by the invention is fermented to generate 3, 4-dihydroxy phenyl glycol, N-tetradecyl diethanol amine and 3-phenyl lactic acid. According to the present invention, with the application of the lactobacillus acidophilus CCFM1460, the metagen of the lactobacillus acidophilus CCFM1460 has the good skin barrier repair effect, the cell viability of the damaged keratinocyte and the expression of the FLG, IVL and LOR gene levels can be improved by the bacterial lysate and the fermentation supernatant of the lactobacillus acidophilus CCFM1460, and the expression of the ZO-1 gene level, the OCCLLUDIN gene level and the CLDN gene level can be improved by the bacterial lysate of the lactobacillus acidophilus CCFM1460; therefore, the lactobacillus acidophilus has a huge application prospect in preparation of external or oral medicines or cosmetics for repairing the skin barrier.

The invention discloses lactobacillus reuteri CCFM1502 capable of up-regulating skin ceramide synthesis and reducing skin inflammation and a metagen of the lactobacillus reuteri CCFM1502, and belongs to the technical field of microorganisms and medicines. The lactobacillus reuteri CCFM1502 provided by the invention can remarkably promote synthesis of ceramide when being externally used and orally taken, and can reduce skin inflammation response of mice after being orally taken. Specifically, the strain lysate and the fermentation supernatant both can promote HaCaT cells to secrete ceramide; the total amount of ceramide in skin can be up-regulated by oral administration of viable bacteria and metabiotics of the lactobacillus reuteri, apparent indexes of the skin can be regulated and controlled, inflammatory reactions in vivo and tissues can be reduced, and particularly, the effect of fermentation supernate of the lactobacillus reuteri is optimal. And the thallus components and viable bacteria have obvious effects in promoting the expression of anti-inflammatory factors in skin tissues. Therefore, the lactobacillus reuteri has a huge application prospect in preparation of a product for promoting synthesis of the natural active ingredient ceramide of the skin.

The invention relates to the technical field of biology, in particular to a lysis solution for rapidly extracting bacterial nucleic acid and a rapid nucleic acid extraction method based on the bacterial lysis solution and magnetic bead separation and enrichment. The lysate is prepared from 50m of Mtris (pH = 7.5), 20mM of EDTA (Ethylene Diamine Tetraacetic Acid), 0.7 M of NaCl, 1.5 M of guanidine isothiocyanate, 1M of guanidine hydrochloride, 0.2 percent of SDS (Sodium Dodecyl Sulfate), 1.5 percent of Tween-20, 1.5 percent of Triton X-100 and 1 percent of PEPPG F68. The extraction method comprises the steps of sample pretreatment and cracking, magnetic bead combination, magnetic bead washing, magnetic bead redissolution and magnetic bead separation, and can be used for treating Gram-positive bacterium and Gram-negative bacterium samples. Silicon hydroxyl magnetic beads with specific particle sizes are adopted, a 2mM NaOH solution is used for washing, and a Tris-HCl (pH = 7.9) solution is used for redissolving. The lysate can be used for preparing a reagent for rapidly extracting bacterial nucleic acid, the extraction method can be applied to bacterial detection or molecular biology experiments, the nucleic acid extraction time is effectively shortened to be within 10 minutes, and an efficient and reliable technical means is provided for related research and detection work.

The application belongs to the technical field of bacteria identification, and discloses a multi-dimensional bacteria spectrum acquisition method, a bacteria identification method and an application device, wherein the multi-dimensional bacteria spectrum acquisition method comprises the following steps: cracking a bacteria suspension by using ultrasonic waves to obtain a bacteria lysate, mixing a plurality of surface-enhanced Raman scattering concentrated suspension substrates with the bacteria lysate respectively to obtain a plurality of mixed liquids, forming a liquid film by using the plurality of mixed liquids, performing surface-enhanced Raman scattering analysis on the liquid film, and obtaining multi-dimensional surface-enhanced Raman scattering bacteria spectrum data. The application can acquire multi-dimensional spectrum information of bacteria, and then realizes rapid and accurate detection and identification of bacteria samples.

The application discloses a strain of fermented Lactobacillus muciadis CCFM1401 based on multi-target skin barrier repair and a postbiotic thereof, and belongs to the technical fields of microorganisms and medicines. The bacterial lysate of the fermented Lactobacillus muciadis CCFM1401 provided by the application can improve the cell activity of damaged keratinocytes and the expression levels of FLG, LOR, IVL, ZO-1, Occludin and CLDN genes in the aspect of external use. The live bacteria and the postbiotic (including the bacterial lysate and the fermentation supernatant) of the fermented Lactobacillus muciadis CCFM1401 can reduce TEWL, up-regulate the water content of the stratum corneum, reduce inflammatory reactions (such as skin histamine and serum IgE), and also up-regulate the expression of skin barrier function and structural proteins. Therefore, the fermented Lactobacillus muciadis has a great application prospect in the preparation of external or oral drugs for repairing skin barrier, and in the preparation of food, health products or cosmetics.

This invention relates to a L. casei / KGM synbiotic comprises: Lactobacillus, its bacterial lysate, and fermentation products, wherein the Lactobacillus is selected from one or more of the following group: Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus rhamnosus, and Lactobacillus paracasei; a polysaccharide; preferably, the polysaccharide is konjac glucomannan; and a wall material; wherein the Lactobacillus or its bacterial lysate and fermentation products are coupled with the polysaccharide, and the wall material encapsulates the coupled material. The present invention provides... L. casei / KGM Synbiotic is easy to use as a poultry feed additive and can effectively treat or prevent intestinal diseases such as enteritis in poultry.

The present application relates to a kind of synbiotic preparation, comprising: probiotic or its bacterial lysate, fermentation product, wherein probiotic is one or more selected from the following group: Bifidobacterium, Streptococcus, Lactobacillus, Saccharomycete, Escherichia coli;Prebiotic is one or more selected from the following group: breast milk oligosaccharide, fructo-oligosaccharide, inulin, lactulose, galacto-oligosaccharide, soybean oligosaccharide, resistant dextrin, xylo-oligosaccharide, isomalto-oligosaccharide, chitooligosaccharide;And wall material;The probiotic or its bacterial lysate, fermentation product is coupled with prebiotic, and wall material is wrapped in the coupling product.The synbiotic preparation of the application is simple, no chemical drug or antibiotic component is added, can repair damaged intestinal mucosal barrier, reduce intestinal permeability, regulate immune balance, optimize flora structure, so as to more effectively treat colitis.In addition, it is convenient to use, easy to promote in farm.

This invention discloses a metabiotic prepared from a strain of *Bifidobacterium adolescentis* that promotes host collagen synthesis, belonging to the fields of microbial technology and pharmaceutical technology. The metabiotic of *Bifidobacterium adolescentis* CCFM1386 provided by this invention has a good effect on promoting host collagen synthesis, improving skin moisture and elasticity, and simultaneously enhancing skin's antioxidant capacity and maintaining collagen homeostasis. Specifically, in vitro, bacterial lysate promotes the activity of LH1 enzyme in HSF cells; in vitro, it increases the content of COLⅠ and COLⅢ and the activity of LH1 enzyme in the self-fermentation supernatant; oral administration of inactivated bacterial cells increases collagen content; oral administration of the self-fermentation supernatant increases the activity of LH1, P4H, and LOX enzymes, promotes collagen synthesis, and increases collagen content. Therefore, this *Bifidobacterium adolescentis* has great application potential in the preparation of oral drugs that promote host collagen synthesis, as well as in the preparation of food, health products, or cosmetics.

The invention discloses application of Phocaecola massiliensis in preparation of a product for treating and / or improving ulcerative colitis, and belongs to the technical field of biological medicine and microbiology. The application of the Phocaecola massiliensis strain from the human body in preparation of the product for treating and / or improving the ulcerative colitis is provided for the first time, and a new direction is provided for treating and / or improving the ulcerative colitis. According to the present invention, the Phocaeola massiliensis is firstly provided as the component of the product for treating and / or improving the ulcerative colitis, the Phocaeola massiliensis is used for preparing the pharmaceutical composition or the functional food in the form of the viable bacteria, the inactivated bacteria or the bacterial lysate, and the pharmaceutical composition comprises the effective dose of the bacterial strain and the pharmaceutically acceptable carrier; the product can slow down weight loss, reduce disease activity index score, increase colon length, reduce colon histopathologic score or reduce pro-inflammatory cytokine level.